Neurocrine Biosciences Inc. (NASDAQ:NBIX) will unveil its latest earnings on Wednesday, May 2, 2012. Neurocrine Biosciences discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for the company to break even after the company reported net income of 5 cents per share in the year-earlier quarter. During the past three months, the average estimate has moved up from a loss of 5 cents. Between one and three months ago, the average estimate moved up. It has been unchanged at breaking even during the last month. For the year, analysts are projecting a loss of 17 cents per share, a spike from profit of 67 cents last year.
Past Earnings Performance: Last quarter, the company beat estimates by one cent, coming in at net income of 2 cents per share against an estimate of profit of. The company also topped expectations in the third quarter of the last fiscal year.
Investing Insights: What’s the Future of Microsoft’s Stock?
Wall St. Revenue Expectations: Analysts predict a decline of 13.3% in revenue from the year-earlier quarter to $10.8 million.
Analyst Ratings: Analysts are optimistic about this stock, with eight analysts rating it as a buy, none rating it as a sell and one rating it as a hold.
A Look Back: In the fourth quarter of the last fiscal year, profit fell 46.5% to $1.3 million (3 cents a share) from $2.5 million (5 cents a share) the year earlier, but exceeded analyst expectations. Revenue fell 18.6% to $11.1 million from $13.7 million.
Stock Price Performance: Between February 1, 2012 and April 27, 2012, the stock price fell $2.01 (-20.8%), from $9.65 to $7.64. The stock price saw one of its best stretches over the last year between November 29, 2011 and December 16, 2011, when shares rose for 14 straight days, increasing 27.3% (+$1.69) over that span. It saw one of its worst periods between July 7, 2011 and July 19, 2011 when shares fell for nine straight days, dropping 7% (-59 cents) over that span.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Stories: